Samsung Biologics reports second quarter 2025 financial results

Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion

Recorded Q2'25 consolidated operating profit of KRW 475.6 billion

Solid momentum sustained through capacity ramp-up and stable project execution

INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025.

"Our second quarter results demonstrate continued strong momentum across our business," said John Rim, CEO and President of Samsung Biologics. "With Plant 5 now fully operational, we are leveraging our manufacturing expertise and expanded capacity to deliver seamless, end-to-end CDMO services at scale. We have broadened our portfolio with advancements in antibody-drug conjugates (ADCs) and the launch of research services, Samsung Organoids, further reinforcing our ability to offer a wider range of innovative solutions to clients. Additionally, we are redefining digitalization in biomanufacturing, harnessing advanced digital tools to deliver greater transparency, speed, and value—setting new standards in the industry. These strategic initiatives will continue to strengthen our ability to accelerate client pipelines, while fostering enduring partnerships grounded in quality and operational excellence."

SECOND QUARTER 2025 RESULTS

Samsung Biologics posted consolidated ...